RA Capital Management, L.P. 13D and 13G filings for Kinnate Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-08-14 5:00 pm Sale |
2023-08-14 | 13G | Kinnate Biopharma Inc. KNTE |
RA Capital Management, L.P. | 0 0.000% |
-4,264,144 (Position Closed) |
Filing |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
RA Capital Management, L.P. | 4,264,144 9.700% |
671,092 (+18.68%) |
Filing |
| 2022-02-14 4:11 pm Unchanged |
2021-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
RA Capital Management, L.P. | 3,593,052 8.200% |
0 (Unchanged) |
Filing |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
RA Capital Management, L.P. | 3,593,052 8.300% |
3,593,052 (New Position) |
Filing |